U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CPG Sec. 410.100 *Finished Dosage Form Drug Products in Bulk Containers - Applications of Current Good Manufacturing Practice Regulations*
  1. Search for FDA Guidance Documents

COMPLIANCE POLICY GUIDE (CPG)

CPG Sec. 410.100 *Finished Dosage Form Drug Products in Bulk Containers - Applications of Current Good Manufacturing Practice Regulations* September 1987

Final
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

BACKGROUND:

*Questions have arisen concerning the application of the "umbrella" CGMP regulations, 21 CFR Parts 210 and 211 to firms which prepare dosage form drug products in bulk containers, such as tablets in fiber drums, and sterile antibiotic powders in bulk containers. Drug products in such bulk quantities are usually intended for further repacking into conventional retail packages such as bottles of 100 tablets each or vials of an antibiotic powder for reconstitution. These questions of application have, on occasion mistakenly expanded the term "bulk drug" to mean not only ingredients of drug products but also finished dosage forms in large quantities. However, in order to apply Parts 210 and 211 it is important to distinguish drug products in finished dosage forms in bulk containers from bulk drug components (i.e. ingredients intended for use in manufacturing or processing of a drug product.)*

POLICY:

The CGMP regulations set forth in 21 CFR Parts 210 and 211 apply to the preparation of finished dosage forms regardless of whether such drug products are in bulk containers or retail packaged form. This is set forth in 21 CFR 210.3(b)(4) and 211.3(a).

The CGMP regulations do not apply as binding regulations to bulk drug components. They are to be used as guidelines during the inspection of facilities manufacturing drug components (43 FR 45026, TP 42a, 9-29-78).

*Material between asterisks is new or revised*

Issued: 2/9/81
Revised: 9/4/87


Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.

Back to Top